1. Home
  2. SNGX vs MNDR Comparison

SNGX vs MNDR Comparison

Compare SNGX & MNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • MNDR
  • Stock Information
  • Founded
  • SNGX 1987
  • MNDR 2016
  • Country
  • SNGX United States
  • MNDR Singapore
  • Employees
  • SNGX N/A
  • MNDR N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • MNDR
  • Sector
  • SNGX Health Care
  • MNDR
  • Exchange
  • SNGX Nasdaq
  • MNDR Nasdaq
  • Market Cap
  • SNGX 6.5M
  • MNDR 6.8M
  • IPO Year
  • SNGX 1987
  • MNDR 2024
  • Fundamental
  • Price
  • SNGX $1.86
  • MNDR $1.33
  • Analyst Decision
  • SNGX
  • MNDR
  • Analyst Count
  • SNGX 0
  • MNDR 0
  • Target Price
  • SNGX N/A
  • MNDR N/A
  • AVG Volume (30 Days)
  • SNGX 26.0K
  • MNDR 200.0K
  • Earning Date
  • SNGX 05-09-2025
  • MNDR 05-27-2025
  • Dividend Yield
  • SNGX N/A
  • MNDR N/A
  • EPS Growth
  • SNGX N/A
  • MNDR N/A
  • EPS
  • SNGX N/A
  • MNDR N/A
  • Revenue
  • SNGX $2,342.00
  • MNDR $13,968,535.00
  • Revenue This Year
  • SNGX N/A
  • MNDR $188,831.77
  • Revenue Next Year
  • SNGX N/A
  • MNDR $76.44
  • P/E Ratio
  • SNGX N/A
  • MNDR N/A
  • Revenue Growth
  • SNGX N/A
  • MNDR 77.38
  • 52 Week Low
  • SNGX $1.68
  • MNDR $0.23
  • 52 Week High
  • SNGX $14.83
  • MNDR $2.85
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 38.46
  • MNDR N/A
  • Support Level
  • SNGX $1.83
  • MNDR N/A
  • Resistance Level
  • SNGX $2.00
  • MNDR N/A
  • Average True Range (ATR)
  • SNGX 0.10
  • MNDR 0.00
  • MACD
  • SNGX -0.00
  • MNDR 0.00
  • Stochastic Oscillator
  • SNGX 11.11
  • MNDR 0.00

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About MNDR Mobile-health Network Solutions Class A Ordinary Shares

Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services which is also its key revenue generating segment, and Sale of medicine and medical devices. Geographically, it derives revenue from Singapore.

Share on Social Networks: